Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Metagenomi Inc | MGX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.10 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 6.50 - 12.74 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 8.10 | USD |
Metagenomi Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
303.97M | 37.53M | - | 44.76M | -68.26M | -1.82 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Metagenomi News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MGX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.59 | 8.395 | 6.50 | 7.10 | 164,641 | 1.51 | 22.91% |
1 Month | 10.79 | 11.01 | 6.50 | 8.15 | 115,452 | -2.69 | -24.93% |
3 Months | 10.25 | 12.74 | 6.50 | 10.62 | 193,290 | -2.15 | -20.98% |
6 Months | 10.25 | 12.74 | 6.50 | 10.62 | 193,290 | -2.15 | -20.98% |
1 Year | 10.25 | 12.74 | 6.50 | 10.62 | 193,290 | -2.15 | -20.98% |
3 Years | 10.25 | 12.74 | 6.50 | 10.62 | 193,290 | -2.15 | -20.98% |
5 Years | 10.25 | 12.74 | 6.50 | 10.62 | 193,290 | -2.15 | -20.98% |
Metagenomi Description
At Metagenomi, we are creating potentially curative therapeutics using our metagenomics-powered genome editing toolbox.We believe tools with capabilities that go beyond the current technology landscape will be required in order to reach the full therapeutic potential of genome editing. By harnessing the power of metagenomics, the study of genomes recovered from uncultivated organisms in the natural environment, we are discovering and developing asuite of novel genome editing tools with the potential to make any desired therapeutic gene edit, anywhere in the human genome. |